Current Computer-Aided Drug DesignCurrent Computer-Aided Drug DesignCurrent Computer-Aided Drug Design1573-40991875-6697Bentham Science64452710.2174/0115734099247900231016055626ChemistryResearch ArticleComputer-aided Design of Wide-spectrum Coronavirus Helicase NSP13 Cage Inhibitors: A Molecular Modelling ApproachShiryaevVadiminfo@benthamscience.netKlimochkinYuriinfo@benthamscience.netorganic chemistry, Samara State Technical University010720242071027104107012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1573-4099/article/view/644527

Background:The coronavirus helicase NSP13 plays a critical role in its life cycle. The found NSP13 inhibitors have been tested only in vitro but they definitely have the potential to become antiviral drugs. Thus, the search for NSP13 inhibitors is of great importance.

Objective:The goal of the present work was to develop a general approach to the design of ligands of coronaviral NSP13 helicase and to propose on its basis potential inhibitors.

Methods:The structure of the NSP13 protein was refined by molecular dynamics and the cavity, responsible for RNA binding, was chosen as the inhibitor binding site. The potential inhibitor structures were identified by molecular docking and their binding was verified by molecular dynamics simulation.

Results:A number of potential NSP13 inhibitors were identified and the binding modes and probable mechanism of action of potential inhibitors was clarified.

Conclusion:Using the molecular dynamics and molecular docking techniques, we have refined the structure of the coronavirus NSP13 helicase, a number of potential inhibitors, containing cage fragment were proposed and their probable mechanism of action was clarified. The proposed approach is also suitable for the design of ligands interacting with other viral helicases.

Coronavirushelicase NSP13inhibitorsmolecular dynamicsmolecular dockingcage compounds.Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 2020, 19(3), 149-150. doi: 10.1038/d41573-020-00016-0 PMID: 32127666Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 2020, 368(6489), 409-412. doi: 10.1126/science.abb3405 PMID: 32198291Osipiuk, J.; Azizi, S.A.; Dvorkin, S.; Endres, M.; Jedrzejczak, R.; Jones, K.A.; Kang, S.; Kathayat, R.S.; Kim, Y.; Lisnyak, V.G.; Maki, S.L.; Nicolaescu, V.; Taylor, C.A.; Tesar, C.; Zhang, Y.A.; Zhou, Z.; Randall, G.; Michalska, K.; Snyder, S.A.; Dickinson, B.C.; Joachimiak, A. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun., 2021, 12(1), 743. doi: 10.1038/s41467-021-21060-3 PMID: 33531496Alam, I.; Kamau, A.A.; Kulmanov, M.; Jaremko, Ł.; Arold, S.T.; Pain, A.; Gojobori, T.; Duarte, C.M. Functional pangenome analysis shows key features of E protein are preserved in SARS and SARS-CoV-2. Front. Cell. Infect. Microbiol., 2020, 10, 405. doi: 10.3389/fcimb.2020.00405 PMID: 32850499Nandi, S.; Roy, H.; Gummadi, A.; Saxena, A.K. Exploring spike protein as potential target of novel coronavirus and to inhibit the viability utilizing natural agents. Curr. Drug Targets, 2021, 22(17), 2006-2020. doi: 10.2174/1389450122666210309105820 PMID: 33687893Shamsi, A.; Mohammad, T.; Anwar, S.; Amani, S.; Khan, M.S.; Husain, F.M.; Rehman, M.T.; Islam, A.; Hassan, M.I. Potential drug targets of SARS-CoV-2: From genomics to therapeutics. Int. J. Biol. Macromol., 2021, 177, 1-9. doi: 10.1016/j.ijbiomac.2021.02.071 PMID: 33577820Wondmkun, Y.T.; Mohammed, O.A. A review on novel drug targets and future directions for COVID-19 treatment. Biologics, 2020, 14, 77-82. doi: 10.2147/BTT.S266487 PMID: 32921981Jia, Z.; Yan, L.; Ren, Z.; Wu, L.; Wang, J.; Guo, J.; Zheng, L.; Ming, Z.; Zhang, L.; Lou, Z.; Rao, Z. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res., 2019, 47(12), 6538-6550. doi: 10.1093/nar/gkz409 PMID: 31131400Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271. doi: 10.1038/s41422-020-0282-0 PMID: 32020029Kwong, A.D.; Rao, B.G.; Jeang, K.T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov., 2005, 4(10), 845-853. doi: 10.1038/nrd1853 PMID: 16184083Frick, D.; Lam, A. Understanding helicases as a means of virus control. Curr. Pharm. Des., 2006, 12(11), 1315-1338. doi: 10.2174/138161206776361147 PMID: 16611118Shiraki, K.; Yasumoto, S.; Toyama, N.; Fukuda, H. Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster. Viruses, 2021, 13(8), 1547. doi: 10.3390/v13081547 PMID: 34452412Lee, S.; Yoon, K.D.; Lee, M.; Cho, Y.; Choi, G.; Jang, H.; Kim, B.; Jung, D.H.; Oh, J.G.; Kim, G.W.; Oh, J.W.; Jeong, Y.J.; Kwon, H.J.; Bae, S.K.; Min, D.H.; Windisch, M.P.; Heo, T.H.; Lee, C. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br. J. Pharmacol., 2016, 173(1), 191-211. doi: 10.1111/bph.13358 PMID: 26445091Lee, S.; Mailar, K.; Kim, M.I.; Park, M.; Kim, J.; Min, D.H.; Heo, T.H.; Bae, S.K.; Choi, W.; Lee, C. Plant-derived purification, chemical synthesis, and in vitro in vivo evaluation of a resveratrol dimer, viniferin, as an HCV replication inhibitor. Viruses, 2019, 11(10), 890. doi: 10.3390/v11100890 PMID: 31547617Bassetto, M.; Leyssen, P.; Neyts, J.; Yerukhimovich, M.M.; Frick, D.N.; Brancale, A. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication. Eur. J. Med. Chem., 2016, 123, 31-47. doi: 10.1016/j.ejmech.2016.07.035 PMID: 27474921Mayank; Kumar, D.; Kaur, N.; Giri, R.; Singh, N. A biscoumarin scaffold as an efficient anti-Zika virus lead with NS3-helicase inhibitory potential: In vitro and in silico investigations. New J. Chem., 2020, 44(5), 1872-1880. doi: 10.1039/C9NJ05225ABonafoux, D.; Nanthakumar, S.; Bandarage, U.K.; Memmott, C.; Lowe, D.; Aronov, A.M.; Bhisetti, G.R.; Bonanno, K.C.; Coll, J.; Leeman, J.; Lepre, C.A.; Lu, F.; Perola, E.; Rijnbrand, R.; Taylor, W.P.; Wilson, D.; Zhou, Y.; Zwahlen, J.; ter Haar, E. Fragment-based discovery of dual JC virus and BK virus helicase inhibitors. J. Med. Chem., 2016, 59(15), 7138-7151. doi: 10.1021/acs.jmedchem.6b00486 PMID: 27385654Habtemariam, S.; Nabavi, S.F.; Banach, M.; Berindan-Neagoe, I.; Sarkar, K.; Sil, P.C.; Nabavi, S.M. Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy? Arch. Med. Res., 2020, 51(7), 733-735. doi: 10.1016/j.arcmed.2020.05.024 PMID: 32536457Kao, R.Y.; Tsui, W.H.W.; Lee, T.S.W.; Tanner, J.A.; Watt, R.M.; Huang, J.D.; Hu, L.; Chen, G.; Chen, Z.; Zhang, L.; He, T.; Chan, K.H.; Tse, H.; To, A.P.C.; Ng, L.W.Y.; Wong, B.C.W.; Tsoi, H.W.; Yang, D.; Ho, D.D.; Yuen, K.Y. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem. Biol., 2004, 11(9), 1293-1299. doi: 10.1016/j.chembiol.2004.07.013 PMID: 15380189Yang, N.; Tanner, J.A.; Wang, Z.; Huang, J.D.; Zheng, B.J.; Zhu, N.; Sun, H. Inhibition of SARS coronavirus helicase by bismuth complexes. Chem. Commun., 2007, 42(42), 4413-4415. doi: 10.1039/b709515e PMID: 17957304Sarafanios, S.G.; Adedeji, A.O. WO Patent Appl. 2013 188887 A1, 2013.Lee, C.; Lee, J.M.; Lee, N.R.; Kim, D.E.; Jeong, Y.J.; Chong, Y. Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives. Bioorg. Med. Chem. Lett., 2009, 19(16), 4538-4541. doi: 10.1016/j.bmcl.2009.07.009 PMID: 19625187Kim, M.K.; Yu, M.S.; Park, H.R.; Kim, K.B.; Lee, C.; Cho, S.Y.; Kang, J.; Yoon, H.; Kim, D.E.; Choo, H.; Jeong, Y.J.; Chong, Y. 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). Eur. J. Med. Chem., 2011, 46(11), 5698-5704. doi: 10.1016/j.ejmech.2011.09.005 PMID: 21925774Yoon, H.J.; Kim, M.K.; Mok, H.J.; Chong, Y.H. Selective Anti-HCV activity of 6,7-Bis-O-Arylmethyl-5,6,7-Trihydroxychromone derivatives. Bull. Korean Chem. Soc., 2012, 33(8), 2803-2805. doi: 10.5012/bkcs.2012.33.8.2803Lee, C.; Lee, J.M.; Lee, N.R.; Jin, B.S.; Jang, K.J.; Kim, D.E.; Jeong, Y.J.; Chong, Y. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase. Bioorg. Med. Chem. Lett., 2009, 19(6), 1636-1638. doi: 10.1016/j.bmcl.2009.02.010 PMID: 19233643Kesel, A. The bananins: New anticorona-RNA-viral agents with unique structural signature. Antiinfect. Agents Med. Chem., 2006, 5(2), 161-174. doi: 10.2174/187152106776359039Tanner, J.A.; Zheng, B.J.; Zhou, J.; Watt, R.M.; Jiang, J.Q.; Wong, K.L.; Lin, Y.P.; Lu, L.Y.; He, M.L.; Kung, H.F.; Kesel, A.J.; Huang, J.D. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol., 2005, 12(3), 303-311. doi: 10.1016/j.chembiol.2005.01.006 PMID: 15797214Mohammad, T.S.H.; Gupta, Y.; Reidl, C.T.; Nicolaescu, V.; Gula, H.; Durvasula, R.; Kempaiah, P.; Becker, D.P. In silicobinding of 2-aminocyclobutanones to SARS-CoV-2 Nsp13 helicase and demonstration of antiviral activity. Int. J. Mol. Sci., 2023, 24(6), 5120. doi: 10.3390/ijms24065120 PMID: 36982188Jo, S.; Kim, T.; Iyer, V.G. Im, W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem., 2008, 29(11), 1859-1865. doi: 10.1002/jcc.20945 PMID: 18351591Brooks, B.R.; Brooks, C.L., III; Mackerell, A.D., Jr; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A.R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M. Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R.W.; Post, C.B.; Pu, J.Z.; Schaefer, M.; Tidor, B.; Venable, R.M.; Woodcock, H.L.; Wu, X.; Yang, W.; York, D.M.; Karplus, M. CHARMM: The biomolecular simulation program. J. Comput. Chem., 2009, 30(10), 1545-1614. doi: 10.1002/jcc.21287 PMID: 19444816Lee, J.; Cheng, X.; Swails, J.M.; Yeom, M.S.; Eastman, P.K.; Lemkul, J.A.; Wei, S.; Buckner, J.; Jeong, J.C.; Qi, Y.; Jo, S.; Pande, V.S.; Case, D.A.; Brooks, C.L., III; MacKerell, A.D., Jr; Klauda, J.B. Im, W. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/openMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput., 2016, 12(1), 405-413. doi: 10.1021/acs.jctc.5b00935 PMID: 26631602Huang, J.; MacKerell, A.D., Jr CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem., 2013, 34(25), 2135-2145. doi: 10.1002/jcc.23354 PMID: 23832629Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem., 2005, 26(16), 1781-1802. doi: 10.1002/jcc.20289 PMID: 16222654Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph., 1996, 14(1), 33-38. doi: 10.1016/0263-7855(96)00018-5Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera?A visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25(13), 1605-1612. doi: 10.1002/jcc.20084 PMID: 15264254Gowers, R.J.; Linke, M.; Barnoud, J.; Reddy, T.J.E.; Melo, M.N.; Seyler, S.L.; Dotson, D.L.; Domanski, J.; Buchoux, S.; Kenney, I.M.; Beckstein, O. MDAnalysis: A Python package for the rapid analysis of molecular dynamics simulations. Proceedings of the 15th Python in Science Conference, 2016, pp. 98-105. doi: 10.25080/Majora-629e541a-00eMichaud-Agrawal, N.; Denning, E.J.; Woolf, T.B.; Beckstein, O. MDAnalysis: A toolkit for the analysis of molecular dynamics simulations. J. Comput. Chem., 2011, 32(10), 2319-2327. doi: 10.1002/jcc.21787 PMID: 21500218ACD ChemSketch. Advanced Chemistry Development. 2015. Available from: www.acdlabs.comHanwell, M.D.; Curtis, D.E.; Lonie, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform., 2012, 4(1), 17. doi: 10.1186/1758-2946-4-17 PMID: 22889332Koes, D.R.; Baumgartner, M.P.; Camacho, C.J. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J. Chem. Inf. Model., 2013, 53(8), 1893-1904. doi: 10.1021/ci300604z PMID: 23379370Newman, J.A.; Douangamath, A.; Yadzani, S.; Yosaatmadja, Y.; Aimon, A.; Brandão-Neto, J.; Dunnett, L.; Gorrie-stone, T.; Skyner, R.; Fearon, D.; Schapira, M.; von Delft, F.; Gileadi, O. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun., 2021, 12(1), 4848. doi: 10.1038/s41467-021-25166-6 PMID: 34381037Dassault Systèmes. BIOVIA, Discovery studio visualiser., 2019. Available from: https://discover.3ds.com/discovery-studio-visualizer-download?gcl id=Cj0KCQjw_5unBhCMARIsACZyzS3LvCEwLJ4bXlKX30QKlP-jvjHjIcJLZnoqdJIW6DevTKusfqCYs7kaAiHHEALw_wcBPerez-Lemus, G.R.; Menéndez, C.A.; Alvarado, W.; Byléhn, F.; de Pablo, J.J. Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors. Sci. Adv., 2022, 8(1), eabj4526. doi: 10.1126/sciadv.abj4526 PMID: 34995115Taylor, R.D.; MacCoss, M.; Lawson, A.D.G. Rings in drugs. J. Med. Chem., 2014, 57(14), 5845-5859. doi: 10.1021/jm4017625 PMID: 24471928Shiryaev, V.A.; Klimochkin, Y.N. Heterocyclic inhibitors of viroporins in the design of antiviral compounds. Chem. Heterocycl. Compd., 2020, 56(6), 626-635. doi: 10.1007/s10593-020-02712-6 PMID: 32836315